Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Suvi-Katri Leivonen, PhD, Judit Jørgensen, MD PhD, Thomas Stauffer Larsen, MD PhD, Annika Pasanen, MD PhD, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Helle M Toldbod, PhD, Francesco d'Amore, MD PhD, Sirpa Leppa, MD PhD

Blood (2019) 134 (Supplement_1): 5314.

https://doi.org/10.1182/blood-2019-129113

Published: 2019

Journal Articles

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

Ida Monrad, MSc, Charlotte Madsen, Kristina Lauridsen, Bent Honoré, Trine Lindhardt Plesner, Stephen Hamilton-Dutoit, MD, Francesco d'Amore, MD, Maja Ludvigsen, MSc, PhD

Blood (2019) 134 (Supplement_1): 2805.

https://doi.org/10.1182/blood-2019-122651

Published: 2019

Journal Articles

Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma

Johanne Marie Holst, MD, Martin Bjerregaard Pedersen, MD, PhD, Marcus C Hansen, MSc, Trine Lindhardt Plesner, Henrik Frederiksen, MD, Michael Møller, Stephen Hamilton-Dutoit, Peter Noergaard, Bo Kok Mortensen, Danilo Fiore, PhD, Chao Wang, Weiwei Zhang, Wayne Tam, MD PhD, Maja Ludvigsen, MSc, PhD, Wing C. Chan, MD, Giorgio Inghirami, MD, Francesco d'Amore, MD

Blood (2019) 134 (Supplement_1): 2776.

https://doi.org/10.1182/blood-2019-131465

Published: 2019

Journal Articles

Characterization of Soluble Immune Checkpoint Protein PD-1, PD-L1 and PD-L2 Levels in Different Types of Lymphoid Malignancies

Julie Bondgaard Mortensen, MS, Vladimirova Yoanna, B.Sc, Ida Monrad Hansen, B.Sc., Mette Bjerre, M.Sc. PhD, Francesco d'Amore, MD

Blood (2018) 132 (Supplement 1): 5306.

https://doi.org/10.1182/blood-2018-99-114509

Published: 2018

Journal Articles

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Francesco d'Amore, MD, Sirpa Leppä, MD, Maria Gomes da Silva, MD PhD, Thomas Relander, Grete Fossum Lauritzsen, Peter De Nully Brown, Antonio Pezzutto, Jeanette K. Doorduijn, MD PhD, Eckhart Weidmann, Michel van Gelder, Achiel Van Hoof, Ilse Christiansen, Unn Merete Fagerli, MD PhD, Hans Hagberg, MD, P.J. Lugtenburg, Jan Walewski, Ka Lung Wu, Hilde Maria Demuynck, Rob Fijnheer, Jacob H. Christensen, Milada Jankovská, MD, Pär L. Josefsson, Hanneke Kluin-Nelemans, Jose Mario Mariz, MD, Mats A. Merup, Thomas Noesslinger, Eric Van Den Neste, Josée M Zijlstra, MD, Georg Hopfinger, MD, VIT Prochazka, MD, Esa Jantunen, MD PhD, Ludmila Boudova, Jose Cabecadas, Andreas Chott, Jan M.A. Delabie, MD PhD, Laurence de Leval, MD, Arjan Diepstra, Marja-Liisa Karjalainen-Lindsberg, MD PhD, Peter Noergaard, Andreas Rosenwald, Grzegorz Rymkiewicz, Christer Sundström, Lorenz Truemper, MD, Gerald Wulf, MD, Lauren Chong, MSc, Alyssa Bouska, PhD, Lynette Smith, Christian Gisselbrecht, Marita Ziepert, PhD, Markus Loeffler, MD, Knut Liestol, Christian Steidl, MD, Randy D. Gascoyne, MD, David W. Scott, PhDMD,FRACP,FRCPA, Bettina Altmann, PhD, Javeed Iqbal, §, Wing C Chan, MD, Helle Toldbod, MS,PhD

Blood (2018) 132 (Supplement 1): 998.

https://doi.org/10.1182/blood-2018-99-110429

Published: 2018

Journal Articles

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

Bettina Altmann, PhD, Gerald Wulf, MD, Lorenz Truemper, MD, Francesco d'Amore, MD, Thomas Relander, Helle Toldbod, MS,PhD, Jan M.A. Delabie, MD PhD, Andreas Rosenwald, Marita Ziepert, PhD, Markus Loeffler, MD

Blood (2018) 132 (Supplement 1): 1622.

https://doi.org/10.1182/blood-2018-99-112076

Published: 2018

Journal Articles

The Impact of Pre-Therapeutic Haemoglobin Levels on the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Anthracycline Containing Chemotherapy before and after the Introduction of Rituximab: A Nation-Wide Cohort Study

Michael Roost Clausen, MD, Sinna Pilgaard Ulrichsen, MSc, Thomas Stauffer Larsen, MD PhD, Bodil Himmelstrup, MD PhD, Dorthe Rønnov-Jessen, MD, Per Trøllund Pedersen, MD, Jakob Madsen, MD, Robert Schou Pedersen, MD, Pär Josefsson, MD PhD, Jette Sønderskov Gørløv, MD, Mette Nørgaard, MD PhD, Francesco d'Amore, MD PhD

Blood (2017) 130 (Supplement 1): 1566.

https://doi.org/10.1182/blood.V130.Suppl_1.1566.1566

Published: 2017

Journal Articles

Lympho- and Myeloproliferative Malignancies Occurring in the Same Host: Description of a Nationwide Discovery Cohort

Johanne Marie Holst, MD, Trine Lindhardt Plesner, Martin Bjerregård Pedersen, MD PhD, Maja Ludvigsen, MSc, PhD Ass.prof, Henrik Frederiksen, Michael Boe Moeller, Rui Wang, Wayne Tam, MD PhD, Giorgio Inghirami, MD, Francesco d'Amore, MD PhD

Blood (2017) 130 (Supplement 1): 1525.

https://doi.org/10.1182/blood.V130.Suppl_1.1525.1525

Published: 2017

Journal Articles

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Blood (2017) 130 (Supplement 1): 822.

https://doi.org/10.1182/blood.V130.Suppl_1.822.822

Published: 2017

Journal Articles

Elevated Pre-Therapeutic Serum Levels of Soluble Programmed Death 1 Protein (sPD-1) Identify DLBCL Patients with Adverse Prognostic Features

Julie Bondgaard Mortensen, MS, Ida Monrad Hansen, B.Sc., Michael Roost Clausen, MD, Mette Bjerre, M.Sc.PhD, Francesco d'Amore, MD PhD

Blood (2017) 130 (Supplement 1): 4148.

https://doi.org/10.1182/blood.V130.Suppl_1.4148.4148

Published: 2017

Journal Articles

High Intratumoral Galectin-1 Is Associated with Adverse Outcome in ALK-Negative, CD30-Positive Peripheral T-Cell Lymphomas

Johanne Marie Holst, MD, Maja Ludvigsen, MSc, PhD Ass.prof, Stephen Dutoit, Knud Bendix, Trine Lindhardt Plesner, Peter Noergaard, MD, Michael Boe Møller, Torben Steiniche, Gabriel Rabinovich, PhD, Francesco d'Amore, MD PhD, Martin Bjerregård Pedersen, MD PhD

Blood (2017) 130 (Supplement 1): 4079.

https://doi.org/10.1182/blood.V130.Suppl_1.4079.4079

Published: 2017

Journal Articles

Low Serum Galectin-1 Levels Predict Future Lymphoma Development in HIV-Positive Patients

Maja Ludvigsen, MSc PhD, Maja Ølholm Vase, MD PhD, Rikke Hjortebjerg, MSc, Irma Petruskevicius, MD, Court Pedersen, Gitte Pedersen, Betina Sørensen, Mette Bjerre, Niels Obel, Bent Honoré, Carsten Schade Larsen, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 2945.

https://doi.org/10.1182/blood.V128.22.2945.2945

Published: 2016

Journal Articles

High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL

Maja Ludvigsen, MSc PhD, Maja Ølholm Vase, MDPhD, Knud Bendix, Stephen Hamilton-Dutoit, Gabriel A Rabinovich, PhD, Michael Boe Moeller, Court Pedersen, Gitte Pedersen, Niels Obel, Carsten Schade Larsen, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 4142.

https://doi.org/10.1182/blood.V128.22.4142.4142

Published: 2016

Journal Articles

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Michael Roost Clausen, MD, Sirpa Leppa, MD, Peter de Nully Brown, MD, Jette Soenderskov Goerloev, MD, Michael Panny, MD, Wolfgang Willenbacher, MD, Ida Blok Sillesen, MD, Erik Segel, MD, Hans Bentzen, MD, Michael Thorsgaard, MD, Elisa Jacobsen Pulczynski, MD, Peter Kamper, MD, Lars C. Gormsen, MD, Julie Mortensen, MDcal Student, Grethe Lauritzsen, MD, Thomas Relander, MD PhD, Francesco d'Amore, MD PhD

Blood (2016) 128 (22): 1782.

https://doi.org/10.1182/blood.V128.22.1782.1782

Published: 2016

Journal Articles

Upfront Rituximab Maintenance after Induction Therapy Improves Outcome and Reduces the Risk of Histological Transformation in Patients with Follicular Lymphoma - Real World Data from a Danish Population-Based Cohort

Charlotte Madsen, MD, Michael Roost Clausen, MD, Maja Ludvigsen, MSc PhD, Trine Lindhardt Plesner, MD, Francesco d'Amore, MD

Blood (2016) 128 (22): 1783.

https://doi.org/10.1182/blood.V128.22.1783.1783

Published: 2016

Journal Articles

Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Henrik Cederleuf, MD, Martin BjerregÃ¥rd Pedersen, MD PhD, Mats Jerkeman, MD PhD, Thomas Relander, MD PhD, Francesco d'Amore, MD, Fredrik Ellin, MD MSc

Blood (2015) 126 (23): 340.

https://doi.org/10.1182/blood.V126.23.340.340

Published: 2015

Journal Articles

Absence of Anaplastic Large Cell Lymphoma Cases in a Large Cohort of Danish Women with Breast Implants: Results of a Nationwide, Population-Based Study,

Maja Ølholm Vase, MD, Søren Friis, MD, Andrea Bautz, MSc, Henrik Toft Sørensen, MD, DMSci, Francesco d'Amore, MD, DMSci

Blood (2011) 118 (21): 3689.

https://doi.org/10.1182/blood.V118.21.3689.3689

Published: 2011

Journal Articles

Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging

Tarec Christoffer El-Galaly, Francesco d'Amore, MD, DMSci, Peter de Nully Brown, Ilse Christiansen, Lena Specht, Annika Loft, Anne Bukh, Hans E. Johnsen, Charlotte Madsen, Martin Hutchings

Blood (2011) 118 (21): 2627.

https://doi.org/10.1182/blood.V118.21.2627.2627

Published: 2011

Journal Articles

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

Blood (2011) 118 (21): 331.

https://doi.org/10.1182/blood.V118.21.331.331

Published: 2011

Journal Articles

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Blood (2011) 118 (21): 4110.

https://doi.org/10.1182/blood.V118.21.4110.4110

Published: 2011

NARROW

Molecular Profiling of Aggressive Non-Hodgkin Lymphoma - Results from a Phase 1/2 Preben Study

Glycolytic Biomarkers Predictive of Transformation in Patients with Follicular Lymphoma

Shared Genomic Alterations in Patients with Co-Existing Myeloproliferative Neoplasms and Angioimmunoblastic T-Cell Lymphoma

Characterization of Soluble Immune Checkpoint Protein PD-1, PD-L1 and PD-L2 Levels in Different Types of Lymphoid Malignancies

Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant

Alemtuzumab Added to CHOP for Treatment of Peripheral T-Cell Lymphoma (PTCL) in Previously Untreated Young and Elderly Patients: Pooled Analysis of the International ACT-1/2 Phase III Trials

The Impact of Pre-Therapeutic Haemoglobin Levels on the Outcome of Patients with Diffuse Large B-Cell Lymphoma Treated with Anthracycline Containing Chemotherapy before and after the Introduction of Rituximab: A Nation-Wide Cohort Study

Lympho- and Myeloproliferative Malignancies Occurring in the Same Host: Description of a Nationwide Discovery Cohort

The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK , DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis

Elevated Pre-Therapeutic Serum Levels of Soluble Programmed Death 1 Protein (sPD-1) Identify DLBCL Patients with Adverse Prognostic Features

High Intratumoral Galectin-1 Is Associated with Adverse Outcome in ALK-Negative, CD30-Positive Peripheral T-Cell Lymphomas

Low Serum Galectin-1 Levels Predict Future Lymphoma Development in HIV-Positive Patients

High Intratumoral Expression of Galectin-1 Correlates with Superior Outcome in HIV-Associated DLBCL

The Combination of Pixantrone, Etoposide, Bendamustine and, in CD20+ Tumors, Rituximab (PREBEN) Shows Promising Feasibility/Efficacy in Heavily Pre-Treated Aggressive Lymphomas of B- and T-Cell Phenotype - Results of the Pre-Trial Experience Leading to a Nordic Phase 1/2 Study (the PREBEN Trial)

Upfront Rituximab Maintenance after Induction Therapy Improves Outcome and Reduces the Risk of Histological Transformation in Patients with Follicular Lymphoma - Real World Data from a Danish Population-Based Cohort

Addition of Etoposide to CHOP Is Associated with Improved Outcome in Adult Anaplastic Large Cell Lymphoma Patients: A Nordic Lymphoma Group Study

Absence of Anaplastic Large Cell Lymphoma Cases in a Large Cohort of Danish Women with Breast Implants: Results of a Nationwide, Population-Based Study,

Routine Bone Marrow Biopsy Adds Little Diagnostic Information in Patients with Newly Diagnosed Hodgkin Lymphoma Undergoing PET/CT Staging

High-Dose Chemotherapy and Autologuos Stem Cell Transplantation in Previously Untreated Peripheral T-Cell Lymphoma - Final Analysis of a Large Prospective Multicenter Study (NLG-T-01)

First Interim Safety Analysis of a Phase III Randomized Trial in Newly Diagnosed Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated by Autologous Hematopoietic Stem Cell Transplant,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only